Literature DB >> 29199041

Whole-cell or acellular pertussis vaccination in infancy determines IgG subclass profiles to DTaP booster vaccination.

Saskia van der Lee1, Elisabeth A M Sanders2, Guy A M Berbers3, Anne-Marie Buisman4.   

Abstract

INTRODUCTION: Duration of protection against pertussis is shorter in adolescents who have been immunized with acellular pertussis (aP) in infancy compared with adolescents who received whole-cell pertussis (wP) vaccines in infancy, which is related to immune responses elicited by these priming vaccines. To better understand differences in vaccine induced immunity, we determined pertussis, diphtheria, and tetanus (DTaP) vaccine antigen-specific IgG subclass responses in wP- and aP-primed children before and after two successive DTaP booster vaccinations.
METHODS: Blood samples were collected in a cross-sectional study from wP- or aP-primed children before and 1 month after the pre-school DTaP booster vaccination at age 4 years. Blood samples were collected from two different wP- and aP-primed groups of children before, 1 month and 1 year after an additional pre-adolescent Tdap booster at age 9 years. IgG subclass levels against the antigens included in the DTaP vaccine have been determined with fluorescent-bead-based multiplex immunoassays.
RESULTS: At 4 years of age, the IgG4 proportion and concentration for pertussis, diphtheria and tetanus vaccine antigens were significantly higher in aP-primed children compared with wP-primed children. IgG4 concentrations further increased upon the two successive booster vaccinations at 4 and 9 years of age in both wP- and aP-primed children, but remained significantly higher in aP-primed children.
CONCLUSIONS: The pertussis vaccinations administered in the primary series at infancy determine the vaccine antigen-specific IgG subclass profiles, not only against the pertussis vaccine antigens, but also against the co-administered diphtheria and tetanus vaccine antigens. These profiles did not change after DTaP booster vaccinations later in childhood. The different immune response with high proportions of specific IgG4 in some aP-primed children may contribute to a reduced protection against pertussis. ISRCTN65428640; ISRCTN64117538; NTR4089.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Children; DTaP; IgG subclass antibodies; IgG4; Pertussis vaccination

Mesh:

Substances:

Year:  2017        PMID: 29199041     DOI: 10.1016/j.vaccine.2017.11.066

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters.

Authors:  Ricardo da Silva Antunes; Mariana Babor; Chelsea Carpenter; Natalie Khalil; Mario Cortese; Alexander J Mentzer; Grégory Seumois; Christopher D Petro; Lisa A Purcell; Pandurangan Vijayanand; Shane Crotty; Bali Pulendran; Bjoern Peters; Alessandro Sette
Journal:  J Clin Invest       Date:  2018-08-06       Impact factor: 14.808

Review 2.  Pertussis vaccines and protective immunity.

Authors:  Parul Kapil; Tod J Merkel
Journal:  Curr Opin Immunol       Date:  2019-05-09       Impact factor: 7.486

3.  Assessment of humoral and cell-mediated immune responses to pertussis vaccination: a systematic review protocol.

Authors:  Funbi Akinola; Rudzani Muloiwa; Gregory D Hussey; Violette Dirix; Benjamin Kagina; Edina Amponsah-Dacosta
Journal:  BMJ Open       Date:  2019-06-09       Impact factor: 2.692

4.  Reactivating Immunity Primed by Acellular Pertussis Vaccines in the Absence of Circulating Antibodies: Enhanced Bacterial Control by TLR9 Rather Than TLR4 Agonist-Including Formulation.

Authors:  Floriane Auderset; Marie Ballester; Beatris Mastelic-Gavillet; Paola Fontannaz; Martine Chabaud-Riou; Nathalie Reveneau; Marie Garinot; Noëlle Mistretta; Yuanqing Liu; Paul-Henri Lambert; Martina Ochs; Claire-Anne Siegrist
Journal:  Front Immunol       Date:  2019-07-03       Impact factor: 7.561

Review 5.  Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines.

Authors:  Susanna Esposito; Paola Stefanelli; Norman K Fry; Giorgio Fedele; Qiushui He; Pauline Paterson; Tina Tan; Markus Knuf; Carlos Rodrigo; Catherine Weil Olivier; Katie L Flanagan; Ivan Hung; Iria Lutsar; Kathryn Edwards; Miguel O'Ryan; Nicola Principi
Journal:  Front Immunol       Date:  2019-07-03       Impact factor: 7.561

6.  Dynamics of the Antibody Response After a Third Dose of Measles-Mumps-Rubella Vaccine Indicate a Slower Decline Compared With a Second Dose.

Authors:  Patricia Kaaijk; M Alina Nicolaie; Debbie van Rooijen; Marianne A van Houten; Fiona R van der Klis; Anne-Marie Buisman; Rob S van Binnendijk
Journal:  Open Forum Infect Dis       Date:  2020-10-20       Impact factor: 3.835

Review 7.  Vaccine-Induced Cellular Immunity against Bordetella pertussis: Harnessing Lessons from Animal and Human Studies to Improve Design and Testing of Novel Pertussis Vaccines.

Authors:  Anja Saso; Beate Kampmann; Sophie Roetynck
Journal:  Vaccines (Basel)       Date:  2021-08-07

8.  Age and Primary Vaccination Background Influence the Plasma Cell Response to Pertussis Booster Vaccination.

Authors:  Annieck M Diks; Pauline Versteegen; Cristina Teodosio; Rick J Groenland; Bas de Mooij; Anne-Marie Buisman; Alba Torres-Valle; Martín Pérez-Andrés; Alberto Orfao; Guy A M Berbers; Jacques J M van Dongen; Magdalena A Berkowska
Journal:  Vaccines (Basel)       Date:  2022-01-18

9.  Lack of evidence supporting a role of IFN-β and TGF-β in differential polarization of Bordetella pertussis specific-T cell responses.

Authors:  Ricardo da Silva Antunes; Lorenzo G Quiambao; Ferran Soldevila; Aaron Sutherland; Bjoern Peters; Alessandro Sette
Journal:  Cytokine       Date:  2020-09-29       Impact factor: 3.861

10.  A system-view of Bordetella pertussis booster vaccine responses in adults primed with whole-cell versus acellular vaccine in infancy.

Authors:  Ricardo da Silva Antunes; Ferran Soldevila; Mikhail Pomaznoy; Mariana Babor; Jason Bennett; Yuan Tian; Natalie Khalil; Yu Qian; Aishwarya Mandava; Richard H Scheuermann; Mario Cortese; Bali Pulendran; Christopher D Petro; Adrienne P Gilkes; Lisa A Purcell; Alessandro Sette; Bjoern Peters
Journal:  JCI Insight       Date:  2021-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.